Preclinical evidence supports the potential of ASC blocking/interfering agents, NLRP3 and caspase-1 inhibitors, IL-1/IL-18/IL-33 targeted therapies, bile acid signaling, and microbiome-modulating strategies mainly in IBD. This evidence concerns the gene CASP1 and inflammatory bowel disease.